Preexposure prophylaxis (PrEP) of HIV infection in France: A nationwide cross-sectional study (PREVIC study)

Although preliminary studies showed that preexposure prophylaxis (PrEP) lowers the HIV transmission in individuals with HIV, confirmative trials are ongoing and PrEP is not routinely recommended. The aim of this study was to assess whether individuals with HIV share antiretroviral (ARV) drugs for PrEP and to describe awareness and discussion on PrEP in this population. A cross-sectional survey was conducted in France in 23 representative departments of infectious diseases and internal medicine. Physicians administered an anonymous standardized questionnaire to all individuals with HIV receiving ARVs and followed between 24 and 31 October 2011. The questionnaire included items regarding PrEP (awareness; discussion with their close circle, physician or patients' association; experience), personal sociodemographic characteristics, risk behaviors and HIV status of the participants. Five hundred and ninety three participants were recruited: male 74.2% (men who have sex with men 52.4%, heterosexuals 21.6%), member of patient's association 9.8%. Half of them (50.6%) lived with a stable partner and 35.2% with an HIV-negative partner. Almost half (41.8%) were aware and 29.5% had had discussion about PrEP. In logistic regression, awareness and discussion on PrEP were more frequent: (1) among males, in patients' association members (p< 0.001 for both) and in nonheterosexuals (p=0.023 and 0.057, respectively); (2) among women, in those not living with a stable partner (p=0.035 and p=0.03, respectively) or living with an HIV-negative partner (p=0.049 and p=0.083, respectively). One percent of the participants declared having shared ARVs with someone and 8.3% reported PrEP in their close circle. Men reporting PrEP in their close circle shared ARVs more frequently than those who did not (10.3% vs. 0.2%, p < 0.001). Today, individuals with HIV do not seem to widely share personal ARVs for PrEP with seronegative people. A significant number of individuals with HIV are aware of and commonly discuss PrEP.

[1]  R. B. Kool,et al.  Facts and figures about patient associations in the Netherlands between 2007 and 2009: review of their activities and aims. , 2012, Health policy.

[2]  Anne M Johnson,et al.  Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey , 2012, Sexually Transmitted Infections.

[3]  P. Durieux,et al.  Information about medication in HIV-infected patients and its relation to adherence. , 2012, Swiss medical weekly.

[4]  Wayne T. Steward,et al.  A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV Infection , 2012, PloS one.

[5]  M. Carrieri,et al.  Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France , 2012, AIDS care.

[6]  M. Dybul,et al.  Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study , 2012, PloS one.

[7]  B. Roehr.  Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm , 2011, BMJ : British Medical Journal.

[8]  B. Roehr.  HIV prevention trial in women is abandoned after drugs show no impact on infection rates , 2011, BMJ : British Medical Journal.

[9]  K. Mayer,et al.  Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. , 2011, AIDS patient care and STDs.

[10]  A. Lansky,et al.  Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. , 2011, MMWR. Morbidity and mortality weekly report.

[11]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[12]  M. Mimiaga,et al.  Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use , 2010, Current HIV/AIDS reports.

[13]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[14]  Carole L Palmer,et al.  Information preferences and practices among people living with HIV/AIDS: results from a nationwide survey. , 2005, Journal of the Medical Library Association : JMLA.